Blood-coagulation-promoting products and methods of preparing them
AssigneeCutter Laboratories, Inc.
InventorsGautam Mitra, Michael H. Coan, Shohachi Wada
Life of this patent
Estimating the term…
Abstract
Blood-coagulation-promoting products substantially free of thrombin are prepared from human blood plasma by contacting a human blood plasma fraction containing coagulation Factors II, VII, IX and X with an anion exchanger to adsorb the coagulation Factors, which are subsequently eluted from the anion exchanger. The eluate is treated to generate a substance having Factor VIII Inhibitor Bypassing Activity and being substantially free of thrombin, and activated Factor X.
Claims39
A method of producing a blood-coagulation-promoting preparation substantially free of thrombin from human blood plasma, which comprises
- (a) contacting a human blood plasma fraction containing coagulation Factors II, VII, IX, and X with an anion exchanger to adsorb the coagulation Factors on the anion exchanger,
- (b) eluting the adsorbed coagulation Factors from the anion exchanger,
- (c) treating the eluate containing the coagulation Factors to generate a Factor VIII Inhibitor Bypassing Activity (FEIBA) substance substantially free of thrombin, and
- (d) treating the eluate to stop the generation of a FEIBA substance.
A lyophilized blood-coagulation-promoting composition substantially free of thrombin comprising a product prepared by a process which includes the steps of
- (a) contacting a human blood plasma fraction containing coagulation Factors II, VII, IX, and X with an anion exchanger to adsorb said coagulation Factors on the anion exchanger,
- (b) eluting the adsorbed coagulation Factors from the anion exchanger,
- (c) treating the eluate containing the coagulation Factors to generate a Factor VIII Inhibitor Bypassing Activity (FEIBA) substance substantially free of thrombin,
- (d) treating the eluate to stop the generation of a FEIBA substance, and
- (e) lyophilizing the eluate.
Dependencies are inferred from the claim text.